The Zhitong Finance App learned that the Hong Kong stock prospectus submitted by Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. (abbreviation: Shanghai Shengsheng) on January 13, 2026 expired on July 13, 2026. CICC and Guojin Securities (Hong Kong) were its co-sponsors.

According to the previous prospectus, Shanghai Shengsheng is an integrated temperature control supply chain service provider for the pharmaceutical and life science industry. The core focus is on clinical trial temperature control supply chain services, medical product temperature control supply chain services extended to the commercialization stage, and R&D and manufacturing of temperature control equipment and materials to create comprehensive temperature control supply chain capabilities throughout the life cycle and application scenarios.

According to Frost & Sullivan's report, based on 2024 revenue, Shanghai Shengsheng is the number one pharmaceutical and life science temperature control supply chain service provider in the Chinese market, and the only Chinese company among the top ten clinical trial temperature control supply chain service providers in the world.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.